Ampio Pharmaceuticals, Inc.
ampiopharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Mar 27, 2024. Its latest SEC filing is a 8-K from Jan 29, 2025.
10-K for FY2023, filed Mar 27, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Developed a potential treatment for knee osteoarthritis.
10-K for FY2023, filed Mar 27, 2024
How Were They Changing?
-
Jan 29, 2025
Ampio was dissolved
A court preliminarily approved a proposed settlement of stockholder derivative actions and demands.
Sources
8-K, filed Jan 29, 2025
The filing of this Current Report on Form 8-K is being made solely to comply with the Preliminary Approval Order. The Company is not…View ↗
A different treatment focus
The earlier report described Ampion as a candidate for knee osteoarthritis and COVID-related illness; the latest report described a different potential treatment for knee osteoarthritis.
10-K for FY2020, filed Mar 3, 2021 10-K for FY2023, filed Mar 27, 2024Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) is a pre-revenue stage biopharmaceutical company that until February 2024 was…View ↗
Loading...
